Author: "Demaris, Kendra" / Topic: therapeutics - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Demaris, Kendra"' showing total 3 results

Start Over Author "Demaris, Kendra" Topic therapeutics

Author: Cada, Dennis J., Demaris, Kendra, Levien, Terri L., and Baker, Danial E.
Subjects: *VOMITING treatment, *ANTIEMETICS, *ANTIHISTAMINES, *COMBINATION drug therapy, *CONTROLLED release preparations, *DRUG side effects, *CLINICAL drug trials, *MARKETING, *MEDICAL societies, *PHARMACOLOGY, *REPORT writing, *SERIAL publications, *STUDY skills, *DRUG approval, *VITAMIN B6, *VITAMIN therapy, *THERAPEUTICS
Abstract: The article presents review of Doxylamine Succinate/Pyridoxine HydrochlorideDelayed-ReleaseTablets also known as Diclegis which are being manufactured by Duchesnay Inc. It mentions that that the drug has been approved to be used in pregnant women for treatment of vomiting and nausea but the drug has not been still approved for the treatment of hyperemesis gravidarum. It reports on clinical pharmacology, pharmacokinetics, and warning and precautions associated with Diclegis.
Published: 2013
Full Text: View/download PDF

Author: Cada, Dennis J., Demaris, Kendra, Levien, Terri L., and Baker, Danial E.
Subjects: *MULTIPLE sclerosis treatment, *CLINICAL drug trials, *IMMUNOLOGICAL adjuvants, *INTERFERONS, *NEUROLOGICAL disorders, *NURSING practice, *PHARMACOLOGY, *DRUG approval, *ACCESS to information, *INVESTIGATIONAL drugs, *THERAPEUTICS
Abstract: The article offers information on Teriflunomide, a drug for the treatment of deteriorating forms of multiple sclerosis (MS) in patients. Its properietary name is aubagio, and is used as immunomodulators, and dihydroorotate dehydrogenase inhibitors. Several other therapies used for the treatment of relapsing MS include fingolimod, glatiramer acetate, and interferon beta-1a.
Published: 2013
Full Text: View/download PDF

Author: Cada, Dennis J., Demaris, Kendra, Levien, Terri L., and Baker, Danial E.
Subjects: *PEDICULOSIS, *SCABIES treatment, *ANTIPARASITIC agents, *DRUG storage, *CLINICAL drug trials, *DRUG toxicity, *LICE, *MEDICAL prescriptions, *OINTMENTS, *PEDIATRICS, *PHARMACEUTICAL industry, *PHARMACOLOGY, *SAFETY, *CUTANEOUS therapeutics, *DRUG approval, *THERAPEUTICS
Abstract: The article discusses Ivermectin 0.5% Topical Lotion, which is indicated for the topical treatment of head lice infestation in patients 6 months or older. The topical lotion exhibits pediculicidal activity and is not directly ovicidal. The various pediculicidal and scabicidal agents approved by the U.S. Food and Drug Administration (FDA) are included. Studies evaluating the comparative efficacy of Ivermectin are described. The contraindications, warnings and precautions to be taken are included.
Published: 2012
Full Text: View/download PDF

Books, media, physical & digital resources

Searchworks